18:35 , Jun 7, 2019 |  BC Extra  |  Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

Takeda discontinues amyloidosis trial  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) discontinued the Phase III TOURMALINE-AL1 trial to treat relapsed or refractory systemic amyloid light-chain (AL) amyloidosis after Ninlaro ixazomib plus dexamethasone missed the first of...
00:28 , Jun 7, 2019 |  BioCentury  |  Product Development

How early biomarkers and constant iteration fuel Vertex's R&D efficiency

As Vertex prepares its fourth NDA for a cystic fibrosis drug in six years, EVP of Global Research and CSO David Altshuler credits the biotech’s R&D efficiency to a focus on agents that show more...
22:43 , Jun 4, 2019 |  BC Extra  |  Clinical News

MacroGenics down on detailed OS data for margetuximab

After getting a bump in May on data released ahead of ASCO, MacroGenics lost $3.13 (17%) to $15.58 on Tuesday following detailed overall survival data from the Phase III SOPHIA trial of margetuximab to treat...
00:06 , May 16, 2019 |  BC Extra  |  Clinical News

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's first round of Quick Takes on selected abstracts. Iovance gains on 44%...
13:05 , Apr 25, 2019 |  BC Extra  |  Preclinical News

Engineered Cas9 derivatives avoid T cell reactivity

Arizona State University researchers have engineered Cas9 to avoid pre-existing immunity against the bacterial protein, a safety concern for in vivo CRISPR-Cas9 gene editing. Samira Kiani, an ASU assistant professor who co-led the study, told...
18:41 , Apr 19, 2019 |  BC Week In Review  |  Company News

Allele, SCM partner to develop iPS cell therapies for diabetes

Allele Biotechnology and SCM partnered to develop diabetes therapies using pancreatic beta cells derived from induced pluripotent stem (iPS) cells. Allele Biotechnology & Pharmaceuticals Inc. (San Diego, Calif.) will be responsible for developing the pancreatic...
23:17 , Apr 12, 2019 |  BC Extra  |  Clinical News

Clovis down after discontinuing rucaparib bladder cancer trial

Clovis was off $3.08 (13%) to $20.40 in after-hours trading Friday after the company disclosed that it discontinued the Phase II ATLAS trial of Rubraca rucaparib as monotherapy to treat locally advanced unresectable or metastatic...
21:16 , Apr 12, 2019 |  BC Week In Review  |  Clinical News

Wave down on delay for Huntington disease readouts

Wave lost $7.84 (19%) to $33.91 on April 10 after it said top-line data from two Phase Ib/IIa trials of its antisense oligonucleotide therapies for Huntington disease will be delayed until year end due to...
22:01 , Mar 15, 2019 |  BioCentury  |  Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...
15:48 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology; inflammation

INDICATION: Stroke; shock/trauma Patient and mouse studies suggest inhibiting CCR5 could help treat stroke and traumatic brain injury (TBI). In stroke patients, the absence of a loss-of-function mutant CCR5 allele was associated with the severity...